vivoVerse
PrivateLast Round
Grant
Jul 9, 2024
Total Funding Raised
$4.08M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
vivoVerse is a biotechnology company that provides a high-throughput drug screening and toxicology platform using microfluidics, automated imaging, and AI-driven analysis of C. elegans models.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Biotech Equipment, Medical AI
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting, Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
vivoVerse Comparables
Compare vivoVerse with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| NemaLife | 90% | |
| Phylumtech S.A. | 83% | |
| Magnitude Biosciences | 83% |
vivoVerse Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jul 9, 2024 | ||||
| Grant | Aug 5, 2023 | ||||
| Grant | Jul 8, 2020 | ||||
| Grant | Jul 9, 2019 | ||||
| Grant | Oct 9, 2018 | ||||
Accelerator | Feb 21, 2018 |
Key People
Founding team and executive leadership
vivoVerse Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| MassChallenge Israel | Accelerator |
| National Institute of Environmental Health Sciences | Grant |
| National Institute of Mental Health | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 35% MoM.
- Feb 26, 2025
Grew 23% QoQ, from 13 to 16 employees.
vivoVerse Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about vivoVerse's valuation, stock price, and market status.
Is vivoVerse a public or private company?
vivoVerse is a private company.
What is the current stock price of vivoVerse?
vivoVerse is a private company with no public stock price. No recent secondary market data is available.
How much is vivoVerse worth (valuation)?
Valuation information for vivoVerse is not publicly available.
Can I buy vivoVerse stock?
vivoVerse shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was vivoVerse's last funding round?
vivoVerse's most recent funding round was Grant on July 9, 2024.
Who are the main investors in vivoVerse?
Key investors in vivoVerse include National Institute of Environmental Health Sciences, National Institute of Mental Health.
Will vivoVerse IPO soon?
No public IPO plans have been announced for vivoVerse.
How can I track vivoVerse secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor vivoVerse's secondary market activity and sign up for updates.